U.S. markets open in 26 minutes

Kala Pharmaceuticals, Inc. (KALA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
5.25-0.04 (-0.76%)
At close: 04:00PM EST
5.23 -0.02 (-0.38%)
Pre-Market: 08:45AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close5.29
Bid5.05 x 800
Ask5.25 x 900
Day's Range5.25 - 5.42
52 Week Range4.92 - 97.00
Avg. Volume184,923
Market Cap7.972M
Beta (5Y Monthly)0.95
PE Ratio (TTM)N/A
EPS (TTM)-2.14
Earnings DateNov 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.88
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for KALA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Kala Pharmaceuticals, Inc.
    Technical Assessment: Bullish in the Intermediate-TermThere was a "red wave" after all, just not the one the stock market was expecting. With red flashing on terminals all over Wall Street, Wednesday was just another miserable day to add to the many other miserable days since the bear-market started late last year. We are not sure how to parcel out the blame for Wednesday's weakness. Perhaps on politics, or on poor EPS reports (DIS), or on the "continued" crash in crypto, or on the worries that we will get another hot CPI print this morning.
    Fair Value
    Economic Moat
    22 days agoArgus Research
View more